PATHOLOGY ASSOCIATES OF NEW YORK
Anatomic Pathology Report

PATIENT INFORMATION:
Name: [REDACTED FOR DEMO]
Patient ID: NYP-2025-01147
Date of Birth: 05/18/1963 (Age: 62 years)
Sex: Female
MRN: 7392846

CLINICAL INFORMATION:
62-year-old female with recurrent metastatic breast cancer.
Original diagnosis 2019: Stage IIA invasive ductal carcinoma, ER+/PR+/HER2+ (IHC 3+)
Treated with lumpectomy, chemotherapy, trastuzumab + pertuzumab, and radiation
Developed metastatic disease to liver and lungs in 2024
Liver biopsy performed to confirm metastatic disease and reassess biomarkers

SPECIMEN:
A. Liver, Segment VI, CT-guided core needle biopsy

DATE OF PROCEDURE: January 18, 2025
DATE RECEIVED: January 18, 2025, 10:45 AM  
DATE REPORTED: January 21, 2025, 14:15 PM

================================================================================
FINAL PATHOLOGIC DIAGNOSIS:
================================================================================

LIVER, SEGMENT VI, CORE NEEDLE BIOPSY:
- Metastatic adenocarcinoma, consistent with breast primary
- See immunohistochemistry results below

GROSS DESCRIPTION:
Received in formalin labeled with patient name and "liver biopsy" are three tan-brown tissue cores, 
each measuring up to 1.6 cm in length and 0.12 cm in diameter. Entirely submitted in one cassette.

MICROSCOPIC DESCRIPTION:
Sections show hepatic parenchyma extensively infiltrated by adenocarcinoma arranged in solid nests 
and cords. The tumor cells are moderately pleomorphic with vesicular chromatin and small nucleoli. 
Mitotic figures are present (12 per 10 HPF). The morphologic features are consistent with metastatic 
breast carcinoma. Adjacent hepatocytes show compression and mild reactive changes.

================================================================================
IMMUNOHISTOCHEMISTRY RESULTS:
================================================================================

HORMONE RECEPTOR PANEL:

Estrogen Receptor (ER) - Clone SP1:
  RESULT: POSITIVE
  Tumor cell staining: 85%
  Intensity: Strong (3+)
  H-Score: 255/300
  Allred Score: 8/8
  INTERPRETATION: Strong ER expression maintained from primary tumor

Progesterone Receptor (PR) - Clone 1E2:
  RESULT: POSITIVE
  Tumor cell staining: 65%
  Intensity: Moderate to Strong (2-3+)
  H-Score: 185/300
  Allred Score: 7/8
  INTERPRETATION: PR expression maintained

HER2/NEU ASSESSMENT:

HER2 Immunohistochemistry (PATHWAY 4B5):
  RESULT: 3+ (HER2-POSITIVE)
  Interpretation: Strong complete membrane staining in >10% of tumor cells
  
  Details: Uniform, intense, complete circumferential membrane staining observed in 
  approximately 90% of tumor cells. Strong, "chicken wire" appearance typical of 
  HER2 3+ staining.
  
  Per ASCO/CAP 2023 Guidelines:
  - IHC Score 3+ = HER2-POSITIVE
  - FISH/ISH testing not required (IHC 3+ is definitive for HER2-positive status)
  
  CLINICAL NOTE: This tumor maintains HER2-positive status from the primary tumor. 
  HER2-targeted therapies (trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan, etc.) 
  remain appropriate treatment options.

PROLIFERATION MARKER:

Ki-67 Proliferation Index (Clone MIB-1):
  RESULT: 42%
  Interpretation: High proliferative activity

ADDITIONAL CONFIRMATORY MARKERS:

Cytokeratin 7 (CK7): POSITIVE (diffuse)
GATA3: POSITIVE (diffuse, strong nuclear)
Mammaglobin: POSITIVE (diffuse)
Gross Cystic Disease Fluid Protein-15 (GCDFP-15): POSITIVE (focal)
TTF-1: NEGATIVE
CDX2: NEGATIVE
CK20: NEGATIVE
Arginase-1: NEGATIVE
Hep Par-1: NEGATIVE

INTERPRETATION: Immunophenotype consistent with metastatic breast carcinoma. The tumor 
is negative for hepatocellular markers, confirming this is metastatic disease rather 
than primary liver cancer.

TUMOR GRADE (Modified Bloom-Richardson/Nottingham):
  Tubule formation: Score 2 (moderate tubule formation, 10-75%)
  Nuclear pleomorphism: Score 2 (moderate variation)
  Mitotic count: Score 2 (12 mitoses per 10 HPF)
  TOTAL SCORE: 6/9
  HISTOLOGIC GRADE: 2 (Moderately differentiated)

================================================================================
COMMENT:
================================================================================

The morphologic features and immunophenotype are consistent with metastatic breast carcinoma 
of ductal type. This represents disease recurrence/metastasis from the patient's known 
primary breast cancer diagnosed in 2019.

BIOMARKER COMPARISON:

Primary Tumor (2019):
- ER: Positive (90%)
- PR: Positive (70%)
- HER2: 3+ (IHC positive)
- Grade: 2

Current Metastasis (2025):
- ER: Positive (85%) - MAINTAINED
- PR: Positive (65%) - MAINTAINED
- HER2: 3+ (IHC positive) - MAINTAINED
- Grade: 2 - UNCHANGED

CLINICAL SIGNIFICANCE:

The biomarker profile has remained stable from primary to metastatic disease. This is clinically 
significant because:

1. HER2-POSITIVE STATUS MAINTAINED: The tumor continues to express high levels of HER2 protein, 
   confirming that HER2-targeted therapies remain appropriate. Patient has previously received 
   trastuzumab + pertuzumab.

2. HORMONE RECEPTOR STATUS MAINTAINED: Continued ER/PR positivity suggests endocrine therapy 
   may still play a role, though HER2-targeted therapy is the primary driver of treatment 
   in HER2+ disease.

3. TREATMENT IMPLICATIONS:
   - Patient has progressed after first-line trastuzumab + pertuzumab
   - Second-line options include:
     * Trastuzumab deruxtecan (T-DXd/Enhertu) - FDA approved, superior PFS vs T-DM1
     * T-DM1 (ado-trastuzumab emtansine)
     * Tucatinib + trastuzumab + capecitabine (especially if brain metastases develop)
     * Neratinib + capecitabine
     * Clinical trials with novel HER2-targeted agents

4. BRAIN METASTASIS RISK: HER2-positive breast cancer has higher propensity for CNS metastases. 
   Baseline brain MRI recommended. Consider tucatinib-based therapy which has excellent CNS 
   penetration if brain metastases develop.

5. PROGNOSIS: HER2-positive metastatic breast cancer has improved significantly with modern 
   HER2-targeted therapies. Median overall survival with contemporary treatment approaches 
   exceeds 5 years.

Ki-67 proliferation index of 42% indicates high proliferative activity. This, combined with 
Grade 2 histology, suggests moderately aggressive biology.

TREATMENT RECOMMENDATIONS:

Based on progression after first-line trastuzumab/pertuzumab therapy:

PREFERRED REGIMEN:
- Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks
  * DESTINY-Breast03 trial showed superior PFS and OS compared to T-DM1
  * ORR approximately 80%
  * Important to monitor for interstitial lung disease (ILD)
  * Requires baseline pulmonary function assessment

ALTERNATIVE REGIMENS:
- T-DM1 (if T-DXd contraindicated or unavailable)
- Tucatinib + trastuzumab + capecitabine (particularly if CNS involvement)
- Clinical trial enrollment

MONITORING:
- Restaging imaging every 6-8 weeks initially
- Brain MRI at baseline and periodically (HER2+ disease has high CNS risk)
- Cardiac monitoring (LVEF assessment before and during treatment)
- Pulmonary symptom monitoring (if on T-DXd)

================================================================================
ANCILLARY STUDIES RECOMMENDED:
================================================================================

1. BASELINE IMAGING:
   - Brain MRI (screen for CNS metastases - common in HER2+ disease)
   - PET-CT for complete staging if not recently performed

2. CARDIAC ASSESSMENT:
   - MUGA scan or echocardiogram to assess LVEF (must be â‰¥50% for HER2-targeted therapy)
   - Repeat every 3 months during treatment

3. PULMONARY FUNCTION:
   - Baseline pulmonary function tests if considering T-DXd
   - Patient should report any new cough, dyspnea (ILD risk with T-DXd)

4. ADDITIONAL MOLECULAR TESTING (OPTIONAL):
   - PIK3CA mutation testing (if considering PI3K inhibitor combinations)
   - Circulating tumor DNA (ctDNA) monitoring may help assess treatment response

================================================================================
ELECTRONICALLY SIGNED:
================================================================================
Jennifer Martinez, MD, PhD
Attending Pathologist
Board Certified: Anatomic Pathology and Clinical Pathology
Fellowship Trained: Breast Pathology

DATE/TIME: January 21, 2025 at 14:15 PM EST

Report distributed to: Dr. Sarah Chen (Medical Oncology)
